Daily Newsletter

22 November 2023

Daily Newsletter

22 November 2023

ASHS to buy 60% stake in three radiation therapy centres

The deal is expected to close in the next 60 days, subject to bankruptcy court approval and other customary conditions.

November 21 2023

American Shared Hospital Services (ASHS), a provider of technology solutions for cancer treatment, has agreed to acquire a majority stake of 60% in three radiation therapy cancer centres in Rhode Island.

Under the deal, ASHS will buy a majority stake in Southern New England Regional Cancer Center and Roger Williams Radiation Therapy, which operates these centres, along with some payor contracts, from GenesisCare USA.

These centres are said to be equipped with advanced technology for cancer treatment.

The deal, valued at $2.85m, is part of GenesisCare's Chapter 11 bankruptcy process.

Each of ProspectCharterCARE, LLC d/b/a Roger Williams Medical Center and Care New England have 20% ownership in the target companies.

Completion of the deal is expected in the next 60 days, contingent on bankruptcy court approval, the parties reaching a consent agreement with the Rhode Island Department of Health, and other customary closing conditions.

Through this acquisition, ASHS aims to expand its US footprint.

ASHS executive chairman Ray Stachowiak said: “This is a milestone agreement for our Company that, upon closing, would expand our footprint of owned and operated radiation oncology centres into the US.

“If consummated, the transaction would add three new revenue streams that we expect would be accretive to our base, and we believe, is an effective use of our capital.

“Most importantly, our ownership would preserve the offering of radiation therapy services at the Landmark, Roger Williams and Maddock Centers and will ensure that patients have continued access to high-quality radiation therapy both for those under treatment today, and for those who will require treatment in the future.”

Is it time for the healthcare sector to fully embrace the benefits of digitalization and AI?

Only a handful of approved therapeutic drugs are currently available for the treatment of ARF, all belonging to the solute carrier family 12 member 1 inhibitor. The clinical trial space in ARF consists of almost an equal mix of commercial as well as academic sponsors, with Iran and the US emerging as the key countries for conducting Phase III trials. While the current marketed drug space for ARF has only a handful of treatment options, currently available mid-to-late-stage pipeline drugs are likely to pave the way for a new treatment approach in the future.

Newsletters by sectors

close

Sign up to the newsletter: In Brief

Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Thank you for subscribing

View all newsletters from across the GlobalData Media network.

close